Vor Biopharma INC 10-Q quarterly reports

Vor Biopharma Inc. filed its Q2 2026 Form 10-Q, detailing ongoing clinical trials for telitacicept and significant net losses, while highlighting cash runway into early 2029.

Vor Biopharma Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing its financial condition, results of operations, and cash flows, with a significant focus on the development of its lead product candidate, telitacicept.

Vor Biopharma reported a significant net loss of $2.4 billion for the nine months ended September 30, 2025, driven by a non-cash warrant revaluation and a strategic pivot to its newly in-licensed autoimmune drug, telitacicept.

Vor Biopharma Inc. reports a significant strategic shift to autoimmune diseases with the in-licensing of telitacicept, alongside a major restructuring and leadership overhaul, despite a substantial net loss driven by warrant revaluation.

Vor Biopharma is halting its clinical and manufacturing operations to explore strategic options for maximizing shareholder value.

Vor Biopharma announced its third quarter 2024 financial results, provided updates on its clinical trials for trem-cel and VCAR33 ALLO, and appointed a new Chief Financial Officer.

Vor Biopharma filed an amendment to its quarterly report to disclose a Rule 10b5-1 trading plan adopted by its Chief Medical Officer.

Vor Biopharma's second quarter 2024 results show a net loss of $27.8 million, with ongoing clinical trials for their novel cancer therapies.

Vor Biopharma reported a net loss of $30.8 million for the first quarter of 2024, while highlighting progress in its clinical programs for hematological malignancies.